nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—Edema cerebral—Carmustine—lymphatic system cancer	0.0552	0.0591	CcSEcCtD
Trifluoperazine—Brain oedema—Carmustine—lymphatic system cancer	0.0299	0.032	CcSEcCtD
Trifluoperazine—Sudden death—Teniposide—lymphatic system cancer	0.0297	0.0318	CcSEcCtD
Trifluoperazine—Megacolon—Methotrexate—lymphatic system cancer	0.0241	0.0258	CcSEcCtD
Trifluoperazine—Amenorrhoea—Mechlorethamine—lymphatic system cancer	0.0234	0.0251	CcSEcCtD
Trifluoperazine—CYP1A2—Carmustine—lymphatic system cancer	0.0224	0.536	CbGbCtD
Trifluoperazine—Ileus paralytic—Vincristine—lymphatic system cancer	0.0188	0.0202	CcSEcCtD
Trifluoperazine—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0166	0.0177	CcSEcCtD
Trifluoperazine—Sudden death—Mitoxantrone—lymphatic system cancer	0.0155	0.0166	CcSEcCtD
Trifluoperazine—EBP—Azacitidine—Fludarabine—lymphatic system cancer	0.0127	0.514	CbGdCrCtD
Trifluoperazine—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.0123	0.0131	CcSEcCtD
Trifluoperazine—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0122	0.0131	CcSEcCtD
Trifluoperazine—EBP—Azacitidine—Cytarabine—lymphatic system cancer	0.012	0.486	CbGdCrCtD
Trifluoperazine—Ileus—Vincristine—lymphatic system cancer	0.0115	0.0123	CcSEcCtD
Trifluoperazine—Jaundice—Mechlorethamine—lymphatic system cancer	0.0112	0.012	CcSEcCtD
Trifluoperazine—Retinal disorder—Methotrexate—lymphatic system cancer	0.0111	0.0119	CcSEcCtD
Trifluoperazine—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0107	0.0115	CcSEcCtD
Trifluoperazine—Bronchospasm—Teniposide—lymphatic system cancer	0.00937	0.01	CcSEcCtD
Trifluoperazine—ABCB1—Mitoxantrone—lymphatic system cancer	0.00921	0.22	CbGbCtD
Trifluoperazine—Pancytopenia—Teniposide—lymphatic system cancer	0.00905	0.00969	CcSEcCtD
Trifluoperazine—Amenorrhoea—Mitoxantrone—lymphatic system cancer	0.00904	0.00968	CcSEcCtD
Trifluoperazine—Gait disturbance—Carmustine—lymphatic system cancer	0.00875	0.00937	CcSEcCtD
Trifluoperazine—Dysphagia—Fludarabine—lymphatic system cancer	0.00837	0.00897	CcSEcCtD
Trifluoperazine—Gait disturbance—Vincristine—lymphatic system cancer	0.00835	0.00895	CcSEcCtD
Trifluoperazine—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00806	0.00863	CcSEcCtD
Trifluoperazine—Pancytopenia—Fludarabine—lymphatic system cancer	0.00795	0.00852	CcSEcCtD
Trifluoperazine—Sudden death—Methotrexate—lymphatic system cancer	0.00773	0.00828	CcSEcCtD
Trifluoperazine—Gynaecomastia—Carmustine—lymphatic system cancer	0.00764	0.00818	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00755	0.00809	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00735	0.00787	CcSEcCtD
Trifluoperazine—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00714	0.00764	CcSEcCtD
Trifluoperazine—Anorexia—Mechlorethamine—lymphatic system cancer	0.007	0.0075	CcSEcCtD
Trifluoperazine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00639	0.00684	CcSEcCtD
Trifluoperazine—ABCB1—Vincristine—lymphatic system cancer	0.00634	0.152	CbGbCtD
Trifluoperazine—Agitation—Teniposide—lymphatic system cancer	0.0061	0.00653	CcSEcCtD
Trifluoperazine—Bronchospasm—Bleomycin—lymphatic system cancer	0.00604	0.00647	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00595	0.00638	CcSEcCtD
Trifluoperazine—Leukopenia—Teniposide—lymphatic system cancer	0.00594	0.00636	CcSEcCtD
Trifluoperazine—Pancytopenia—Bleomycin—lymphatic system cancer	0.00583	0.00624	CcSEcCtD
Trifluoperazine—Cardiac arrest—Vincristine—lymphatic system cancer	0.00563	0.00603	CcSEcCtD
Trifluoperazine—Urinary retention—Vincristine—lymphatic system cancer	0.00563	0.00603	CcSEcCtD
Trifluoperazine—Muscular weakness—Carmustine—lymphatic system cancer	0.00547	0.00586	CcSEcCtD
Trifluoperazine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00541	0.0058	CcSEcCtD
Trifluoperazine—Agitation—Fludarabine—lymphatic system cancer	0.00536	0.00574	CcSEcCtD
Trifluoperazine—Dysphagia—Carmustine—lymphatic system cancer	0.00536	0.00574	CcSEcCtD
Trifluoperazine—Leukopenia—Fludarabine—lymphatic system cancer	0.00522	0.00559	CcSEcCtD
Trifluoperazine—Muscular weakness—Vincristine—lymphatic system cancer	0.00522	0.00559	CcSEcCtD
Trifluoperazine—Pruritus—Mechlorethamine—lymphatic system cancer	0.0052	0.00557	CcSEcCtD
Trifluoperazine—Anorexia—Teniposide—lymphatic system cancer	0.00516	0.00553	CcSEcCtD
Trifluoperazine—Cough—Fludarabine—lymphatic system cancer	0.00509	0.00545	CcSEcCtD
Trifluoperazine—Pancytopenia—Carmustine—lymphatic system cancer	0.00509	0.00545	CcSEcCtD
Trifluoperazine—Hypotension—Teniposide—lymphatic system cancer	0.00506	0.00542	CcSEcCtD
Trifluoperazine—Convulsion—Fludarabine—lymphatic system cancer	0.00505	0.00541	CcSEcCtD
Trifluoperazine—Pancytopenia—Vincristine—lymphatic system cancer	0.00486	0.0052	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00483	0.00518	CcSEcCtD
Trifluoperazine—Dyspnoea—Teniposide—lymphatic system cancer	0.00483	0.00517	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00476	0.0051	CcSEcCtD
Trifluoperazine—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00473	0.00507	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00471	0.00505	CcSEcCtD
Trifluoperazine—Decreased appetite—Teniposide—lymphatic system cancer	0.00471	0.00504	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00467	0.005	CcSEcCtD
Trifluoperazine—Rash—Mechlorethamine—lymphatic system cancer	0.00463	0.00496	CcSEcCtD
Trifluoperazine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00463	0.00496	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00459	0.00491	CcSEcCtD
Trifluoperazine—Anorexia—Fludarabine—lymphatic system cancer	0.00454	0.00486	CcSEcCtD
Trifluoperazine—Weight increased—Mitoxantrone—lymphatic system cancer	0.00453	0.00486	CcSEcCtD
Trifluoperazine—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00449	0.00481	CcSEcCtD
Trifluoperazine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00444	0.00476	CcSEcCtD
Trifluoperazine—Nausea—Mechlorethamine—lymphatic system cancer	0.00436	0.00467	CcSEcCtD
Trifluoperazine—Jaundice—Mitoxantrone—lymphatic system cancer	0.00433	0.00464	CcSEcCtD
Trifluoperazine—Urticaria—Teniposide—lymphatic system cancer	0.0043	0.00461	CcSEcCtD
Trifluoperazine—Body temperature increased—Teniposide—lymphatic system cancer	0.00428	0.00459	CcSEcCtD
Trifluoperazine—Erythema—Bleomycin—lymphatic system cancer	0.00428	0.00458	CcSEcCtD
Trifluoperazine—Dyspnoea—Fludarabine—lymphatic system cancer	0.00424	0.00455	CcSEcCtD
Trifluoperazine—Oedema peripheral—Carmustine—lymphatic system cancer	0.00422	0.00453	CcSEcCtD
Trifluoperazine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00414	0.00444	CcSEcCtD
Trifluoperazine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00414	0.00443	CcSEcCtD
Trifluoperazine—Fatigue—Fludarabine—lymphatic system cancer	0.0041	0.0044	CcSEcCtD
Trifluoperazine—Constipation—Fludarabine—lymphatic system cancer	0.00407	0.00436	CcSEcCtD
Trifluoperazine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00399	0.00427	CcSEcCtD
Trifluoperazine—Asthenia—Teniposide—lymphatic system cancer	0.00389	0.00416	CcSEcCtD
Trifluoperazine—ABCB1—Methotrexate—lymphatic system cancer	0.00384	0.0918	CbGbCtD
Trifluoperazine—Pruritus—Teniposide—lymphatic system cancer	0.00383	0.00411	CcSEcCtD
Trifluoperazine—Leukopenia—Bleomycin—lymphatic system cancer	0.00383	0.0041	CcSEcCtD
Trifluoperazine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00376	0.00403	CcSEcCtD
Trifluoperazine—Erythema—Carmustine—lymphatic system cancer	0.00373	0.004	CcSEcCtD
Trifluoperazine—Cough—Bleomycin—lymphatic system cancer	0.00373	0.004	CcSEcCtD
Trifluoperazine—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00371	0.00398	CcSEcCtD
Trifluoperazine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.00354	0.00379	CcSEcCtD
Trifluoperazine—Vision blurred—Carmustine—lymphatic system cancer	0.00352	0.00377	CcSEcCtD
Trifluoperazine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00351	0.00376	CcSEcCtD
Trifluoperazine—Tremor—Carmustine—lymphatic system cancer	0.0035	0.00375	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00349	0.00374	CcSEcCtD
Trifluoperazine—Erythema—Mitoxantrone—lymphatic system cancer	0.00347	0.00372	CcSEcCtD
Trifluoperazine—Agitation—Carmustine—lymphatic system cancer	0.00343	0.00367	CcSEcCtD
Trifluoperazine—Asthenia—Fludarabine—lymphatic system cancer	0.00342	0.00366	CcSEcCtD
Trifluoperazine—Rash—Teniposide—lymphatic system cancer	0.00342	0.00366	CcSEcCtD
Trifluoperazine—Dermatitis—Teniposide—lymphatic system cancer	0.00341	0.00366	CcSEcCtD
Trifluoperazine—Headache—Teniposide—lymphatic system cancer	0.00339	0.00363	CcSEcCtD
Trifluoperazine—Pruritus—Fludarabine—lymphatic system cancer	0.00337	0.00361	CcSEcCtD
Trifluoperazine—Leukopenia—Carmustine—lymphatic system cancer	0.00334	0.00358	CcSEcCtD
Trifluoperazine—Anorexia—Bleomycin—lymphatic system cancer	0.00333	0.00356	CcSEcCtD
Trifluoperazine—Agitation—Vincristine—lymphatic system cancer	0.00327	0.00351	CcSEcCtD
Trifluoperazine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00327	0.0035	CcSEcCtD
Trifluoperazine—Photosensitivity—Methotrexate—lymphatic system cancer	0.00327	0.0035	CcSEcCtD
Trifluoperazine—Hypotension—Bleomycin—lymphatic system cancer	0.00326	0.00349	CcSEcCtD
Trifluoperazine—Convulsion—Carmustine—lymphatic system cancer	0.00323	0.00346	CcSEcCtD
Trifluoperazine—Nausea—Teniposide—lymphatic system cancer	0.00322	0.00345	CcSEcCtD
Trifluoperazine—Leukopenia—Vincristine—lymphatic system cancer	0.00319	0.00342	CcSEcCtD
Trifluoperazine—Dyspnoea—Bleomycin—lymphatic system cancer	0.00311	0.00333	CcSEcCtD
Trifluoperazine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00311	0.00333	CcSEcCtD
Trifluoperazine—Convulsion—Vincristine—lymphatic system cancer	0.00309	0.00331	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00304	0.00326	CcSEcCtD
Trifluoperazine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00303	0.00325	CcSEcCtD
Trifluoperazine—Cough—Mitoxantrone—lymphatic system cancer	0.00303	0.00324	CcSEcCtD
Trifluoperazine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00301	0.00322	CcSEcCtD
Trifluoperazine—Rash—Fludarabine—lymphatic system cancer	0.003	0.00322	CcSEcCtD
Trifluoperazine—Dermatitis—Fludarabine—lymphatic system cancer	0.003	0.00321	CcSEcCtD
Trifluoperazine—Headache—Fludarabine—lymphatic system cancer	0.00298	0.00319	CcSEcCtD
Trifluoperazine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00297	0.00318	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00291	0.00312	CcSEcCtD
Trifluoperazine—Anorexia—Carmustine—lymphatic system cancer	0.0029	0.00311	CcSEcCtD
Trifluoperazine—Hypotension—Carmustine—lymphatic system cancer	0.00285	0.00305	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00283	0.00303	CcSEcCtD
Trifluoperazine—Nausea—Fludarabine—lymphatic system cancer	0.00283	0.00303	CcSEcCtD
Trifluoperazine—Urticaria—Bleomycin—lymphatic system cancer	0.00277	0.00297	CcSEcCtD
Trifluoperazine—Anorexia—Vincristine—lymphatic system cancer	0.00277	0.00297	CcSEcCtD
Trifluoperazine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00276	0.00296	CcSEcCtD
Trifluoperazine—Insomnia—Carmustine—lymphatic system cancer	0.00276	0.00295	CcSEcCtD
Trifluoperazine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00275	0.00295	CcSEcCtD
Trifluoperazine—Hypotension—Vincristine—lymphatic system cancer	0.00272	0.00291	CcSEcCtD
Trifluoperazine—Dyspnoea—Carmustine—lymphatic system cancer	0.00272	0.00291	CcSEcCtD
Trifluoperazine—Somnolence—Carmustine—lymphatic system cancer	0.00271	0.0029	CcSEcCtD
Trifluoperazine—Anorexia—Mitoxantrone—lymphatic system cancer	0.0027	0.00289	CcSEcCtD
Trifluoperazine—Decreased appetite—Carmustine—lymphatic system cancer	0.00265	0.00284	CcSEcCtD
Trifluoperazine—Hypotension—Mitoxantrone—lymphatic system cancer	0.00265	0.00284	CcSEcCtD
Trifluoperazine—Insomnia—Vincristine—lymphatic system cancer	0.00263	0.00282	CcSEcCtD
Trifluoperazine—Constipation—Carmustine—lymphatic system cancer	0.00261	0.00279	CcSEcCtD
Trifluoperazine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00257	0.00275	CcSEcCtD
Trifluoperazine—Decreased appetite—Vincristine—lymphatic system cancer	0.00253	0.00271	CcSEcCtD
Trifluoperazine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00253	0.00271	CcSEcCtD
Trifluoperazine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00252	0.0027	CcSEcCtD
Trifluoperazine—Fatigue—Vincristine—lymphatic system cancer	0.00251	0.00269	CcSEcCtD
Trifluoperazine—Asthenia—Bleomycin—lymphatic system cancer	0.0025	0.00268	CcSEcCtD
Trifluoperazine—Constipation—Vincristine—lymphatic system cancer	0.00249	0.00266	CcSEcCtD
Trifluoperazine—Asthma—Methotrexate—lymphatic system cancer	0.00248	0.00266	CcSEcCtD
Trifluoperazine—Pruritus—Bleomycin—lymphatic system cancer	0.00247	0.00265	CcSEcCtD
Trifluoperazine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00246	0.00264	CcSEcCtD
Trifluoperazine—Eosinophilia—Methotrexate—lymphatic system cancer	0.00246	0.00263	CcSEcCtD
Trifluoperazine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00244	0.00262	CcSEcCtD
Trifluoperazine—Constipation—Mitoxantrone—lymphatic system cancer	0.00242	0.00259	CcSEcCtD
Trifluoperazine—Body temperature increased—Carmustine—lymphatic system cancer	0.00241	0.00258	CcSEcCtD
Trifluoperazine—Pancytopenia—Methotrexate—lymphatic system cancer	0.00236	0.00252	CcSEcCtD
Trifluoperazine—Body temperature increased—Vincristine—lymphatic system cancer	0.0023	0.00246	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00229	0.00245	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00227	0.00243	CcSEcCtD
Trifluoperazine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00225	0.00241	CcSEcCtD
Trifluoperazine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00224	0.0024	CcSEcCtD
Trifluoperazine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00224	0.0024	CcSEcCtD
Trifluoperazine—Drowsiness—Methotrexate—lymphatic system cancer	0.00221	0.00237	CcSEcCtD
Trifluoperazine—Rash—Bleomycin—lymphatic system cancer	0.0022	0.00236	CcSEcCtD
Trifluoperazine—Dermatitis—Bleomycin—lymphatic system cancer	0.0022	0.00236	CcSEcCtD
Trifluoperazine—Asthenia—Carmustine—lymphatic system cancer	0.00219	0.00234	CcSEcCtD
Trifluoperazine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00214	0.0023	CcSEcCtD
Trifluoperazine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00209	0.00224	CcSEcCtD
Trifluoperazine—Asthenia—Vincristine—lymphatic system cancer	0.00209	0.00224	CcSEcCtD
Trifluoperazine—Nausea—Bleomycin—lymphatic system cancer	0.00207	0.00222	CcSEcCtD
Trifluoperazine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00206	0.00221	CcSEcCtD
Trifluoperazine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00203	0.00218	CcSEcCtD
Trifluoperazine—Dizziness—Carmustine—lymphatic system cancer	0.00201	0.00216	CcSEcCtD
Trifluoperazine—Dizziness—Vincristine—lymphatic system cancer	0.00192	0.00206	CcSEcCtD
Trifluoperazine—Rash—Carmustine—lymphatic system cancer	0.00192	0.00206	CcSEcCtD
Trifluoperazine—Dermatitis—Carmustine—lymphatic system cancer	0.00192	0.00206	CcSEcCtD
Trifluoperazine—Headache—Carmustine—lymphatic system cancer	0.00191	0.00204	CcSEcCtD
Trifluoperazine—Rash—Vincristine—lymphatic system cancer	0.00183	0.00196	CcSEcCtD
Trifluoperazine—Dermatitis—Vincristine—lymphatic system cancer	0.00183	0.00196	CcSEcCtD
Trifluoperazine—Headache—Vincristine—lymphatic system cancer	0.00182	0.00195	CcSEcCtD
Trifluoperazine—Nausea—Carmustine—lymphatic system cancer	0.00181	0.00194	CcSEcCtD
Trifluoperazine—Rash—Mitoxantrone—lymphatic system cancer	0.00179	0.00191	CcSEcCtD
Trifluoperazine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00178	0.00191	CcSEcCtD
Trifluoperazine—Headache—Mitoxantrone—lymphatic system cancer	0.00177	0.0019	CcSEcCtD
Trifluoperazine—Erythema—Methotrexate—lymphatic system cancer	0.00173	0.00185	CcSEcCtD
Trifluoperazine—Nausea—Vincristine—lymphatic system cancer	0.00173	0.00185	CcSEcCtD
Trifluoperazine—Nausea—Mitoxantrone—lymphatic system cancer	0.00168	0.0018	CcSEcCtD
Trifluoperazine—Vision blurred—Methotrexate—lymphatic system cancer	0.00163	0.00175	CcSEcCtD
Trifluoperazine—Leukopenia—Methotrexate—lymphatic system cancer	0.00155	0.00166	CcSEcCtD
Trifluoperazine—Cough—Methotrexate—lymphatic system cancer	0.00151	0.00162	CcSEcCtD
Trifluoperazine—Convulsion—Methotrexate—lymphatic system cancer	0.0015	0.0016	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00141	0.00151	CcSEcCtD
Trifluoperazine—Skin disorder—Methotrexate—lymphatic system cancer	0.00137	0.00147	CcSEcCtD
Trifluoperazine—Anorexia—Methotrexate—lymphatic system cancer	0.00135	0.00144	CcSEcCtD
Trifluoperazine—Hypotension—Methotrexate—lymphatic system cancer	0.00132	0.00141	CcSEcCtD
Trifluoperazine—Insomnia—Methotrexate—lymphatic system cancer	0.00128	0.00137	CcSEcCtD
Trifluoperazine—Dyspnoea—Methotrexate—lymphatic system cancer	0.00126	0.00135	CcSEcCtD
Trifluoperazine—Somnolence—Methotrexate—lymphatic system cancer	0.00125	0.00134	CcSEcCtD
Trifluoperazine—Decreased appetite—Methotrexate—lymphatic system cancer	0.00123	0.00131	CcSEcCtD
Trifluoperazine—Fatigue—Methotrexate—lymphatic system cancer	0.00122	0.0013	CcSEcCtD
Trifluoperazine—Urticaria—Methotrexate—lymphatic system cancer	0.00112	0.0012	CcSEcCtD
Trifluoperazine—Body temperature increased—Methotrexate—lymphatic system cancer	0.00112	0.0012	CcSEcCtD
Trifluoperazine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00104	0.00111	CcSEcCtD
Trifluoperazine—Asthenia—Methotrexate—lymphatic system cancer	0.00101	0.00108	CcSEcCtD
Trifluoperazine—Pruritus—Methotrexate—lymphatic system cancer	0.000998	0.00107	CcSEcCtD
Trifluoperazine—Dizziness—Methotrexate—lymphatic system cancer	0.000933	0.001	CcSEcCtD
Trifluoperazine—Rash—Methotrexate—lymphatic system cancer	0.00089	0.000953	CcSEcCtD
Trifluoperazine—Dermatitis—Methotrexate—lymphatic system cancer	0.000889	0.000952	CcSEcCtD
Trifluoperazine—Headache—Methotrexate—lymphatic system cancer	0.000884	0.000947	CcSEcCtD
Trifluoperazine—Nausea—Methotrexate—lymphatic system cancer	0.000838	0.000898	CcSEcCtD
